|Bid||79.35 x 100|
|Ask||79.45 x 100|
|Day's Range||79.07 - 82.08|
|52 Week Range||41.76 - 92.98|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||105.36|
Conference Call and Webcast Scheduled for Monday, April 30 SAN DIEGO , April 23, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report first quarter financial ...
NEW YORK , April 19, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...
SAN DIEGO, April 18, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that new data for once-daily INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD), will be presented at the American Academy of Neurology (AAN) Annual Meeting in Los Angeles, Calif., April 21-27, 2018. Highlighted presentations include analysis of the short- and long-term effects of INGREZZA on TD symptoms by body region, long-term INGREZZA safety and efficacy data from the KINECT 4 Phase III open-label study and data from RE-KINECT, a real-world screening study of patients with possible TD. "The symptoms of tardive dyskinesia are heterogeneous, with each patient experiencing tardive dyskinesia somewhat differently.
Neurocrine Biosciences (NBIX) is a pharmaceutical company with a focus on neurological and endocrine-based diseases and disorders. Its leading product on the market is Ingrezza, a vesicular monoamine transporter 2 (or VMAT2) inhibitor used in the treatment of movement disorders. Ingrezza was approved by the FDA for the treatment of tardive dyskinesia (or TD) in April 2017.
AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug. The agency requested more time to review additional information regarding the results of liver function tests provided by AbbVie in connection with the application for Elagolix in endometriosis-associated pain, the companies said.
AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug. The agency requested more time to review additional information regarding the results of liver function tests provided by AbbVie in connection with the application for Elagolix in endometriosis-associated pain, the companies said. The FDA is now expected to make its decision in the third quarter of 2018, three months later than initially expected.
- FDA requires extended time for review of additional information in New Drug Application (NDA) - Elagolix clinical trial program largest prospective randomized endometriosis trial conducted to date - ...
Who's the world's best hedge fund manager? David Tepper? Stevie Cohen? Try Joe Edelman, a wannabe psychologist with a bead on biotech who has quietly built the best track record of the past two decades.
Teva Pharmaceutical (TEVA) is focused on advancing its specialty assets portfolio, one of its key growth drivers. The company’s specialty products portfolio is made up of Copaxone, Austedo, Fremanezumab, and a number of other assets that are in clinical trials, one of which is Fasinumab.
Neurocrine Biosciences Inc’s (NASDAQ:NBIX): Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The US$7.85B market-cap company announcedRead More...
SAN DIEGO , March 7, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Kevin Gorman , CEO of Neurocrine Biosciences, will present at the following investor conferences: ...
AbbVie Inc. and Neurocrine Biosciences Inc. shares rose 1.7% and 1.1% respectively in premarket trade Wednesday after the companies announced that their drug met its primary endpoint in a phase 3 trial ...
− First of two pivotal Phase 3 studies met primary efficacy endpoint and all ranked secondary endpoints − Results demonstrated elagolix, in combination with low-dose add-back therapy, reduced heavy menstrual ...
On Feb. 14, 2018, Neurocrine Biosciences, Inc. (NBIX) announced the company will file a new drug application (NDA) for opicapone in the first half of 2019 following receipt of the meeting minutes from the January 2018 meeting with the FDA. During that meeting, the FDA did not request that Neurocrine conduct an additional Phase 3 study for opicapone prior to filing the NDA. Opicapone is a peripherally-acting and highly selective inhibitor of catechol-o-methyltransferase (COMT) to be used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors in patients with Parkinson’s disease (PD).
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
SAN DIEGO, Feb. 14, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX), a biotechnology company focused on neurological and endocrine related disorders, today announced that the U.S. Food and Drug Administration (FDA) has provided guidance on the regulatory path forward to support the New Drug Application (NDA) for opicapone, an investigational drug for Parkinson's disease, after receiving meeting minutes from the January 2018 meeting with the FDA. Most importantly, the Neurology Division of the FDA has not requested that Neurocrine conduct an additional Phase III study for opicapone prior to the NDA filing.
The San Diego-based company said it had profit of 7 cents per share. The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings ...
INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $64.5 Million with Approximately 9,100 TRx INGREZZA Net Product Sales of $116.6 Million with Approximately 14,900 TRx Since Commercial Launch ...